Please assess the completion status of the following clinical trial:

Trial Title: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. locally advanced (\>T1) and/or nodal positive (N+) histologically proven adenocarcinoma of the esophagogastreal junction (AEG I-III) or the stomach without distant metastases (M0) and without infiltration of adjacent structures and organs~2. no previous surgical resection~3. no previous cytostatic chemotherapy~4. Age \> 18 years (female and male)~5. ECOG ≤ 2~6. surgical resectability~7. Exclusion of peritoneal carcinomatosis (if clinically suspected) via laparoscopy~8. Leucocytes \> 3.000/µl~9. Platelets \> 100.000/µl~10. Serum creatinin ≤ 1.5x of normal value, or Creatinin-Clearance \> 50 ml/min~11. written informed consent.~12. Ejection fraction \> 50% in echocardiography before start of therapy~Exclusion Criteria:~1. distant metastases or infiltration of adjacent structures or organs and all primarily not resectable stages~2. relapse~3. Hypersensitivity against 5- Fluorouracil, Leucovorin, Oxaliplatin, Cisplatin. Epirubicin and Docetaxel~4. Existence of contraindications against 5- Fluorouracil, Leucovorin, Oxaliplatin, Cisplatin, Epirubicin or Docetaxel~5. Active CHD, Cardiomyopathy or cardiac insufficiency stage III-IV according to NYHA~6. malignant secondary disease, dated back \< 5 years (exception: In-situ-carcinoma of the cervix uteri, adequately treated skin basal cell carcinoma)~7. severe non-surgical accompanying disease or acute infection~8. peripheral polyneuropathy \> NCI Grad II~9. severe liver dysfunction (AST/ALT\>3,5xULN, AP\>6xULN, Bilirubin\>1,5xULN)~10. chronic inflammable gastro-intestinal disease~11. inclusion in another clinical trial~12. pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FLOT (Type: EXPERIMENTAL): Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
- ECF (Type: ACTIVE_COMPARATOR): Epirubicin 50 mg/m2, d1 Cisplatin 60 mg/m², d1 5-FU 200 mg/m², d1-d21 every 3 weeks (q3w) 3 cycles (9 weeks) pre-OP and 3 cycles (9 weeks) post-OP

Based on this trial design, predict the completion outcome and termination type (if applicable).